Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Randomization of Endovascular Treatment in Acute Ischemic Stroke in the Extended Time Window (RESILIENTExt)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04256096
Recruitment Status : Recruiting
First Posted : February 5, 2020
Last Update Posted : February 10, 2021
Sponsor:
Collaborators:
Hospital das Clínicas de Ribeirão Preto
Hospital Geral de Fortaleza
Hospital de Base
Federal University of São Paulo
Fundação Faculdade Regional de Medicina de São José do Rio Preto
UPECLIN HC FM Botucatu Unesp
University of Campinas, Brazil
Irmandade Santa Casa de Misericórdia de Porto Alegre
Universidade Federal do Paraná
Hospital Estadual Central
Hospital Sao Jose do Avai
Irmandade da Santa Casa de Misericordia de Sao Paulo
Federal University of Uberlandia
Instituto de Assistencia Medica ao Servidor Publico Estadual, Sao Paulo
Information provided by (Responsible Party):
SHEILA CRISTINA OURIQUES MARTINS, Hospital de Clinicas de Porto Alegre

Tracking Information
First Submitted Date  ICMJE February 3, 2020
First Posted Date  ICMJE February 5, 2020
Last Update Posted Date February 10, 2021
Actual Study Start Date  ICMJE March 9, 2020
Estimated Primary Completion Date February 1, 2022   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: February 7, 2021)
Modified Rankin Scale scores [ Time Frame: 90 days ]
Distribution of the modified Rankin Scale scores at 90 days (shift analysis). The score range from zero to 6 with higher values indicating a worst functional outcome at 90 days
Original Primary Outcome Measures  ICMJE
 (submitted: February 4, 2020)
Modified Rankin Scale scores [ Time Frame: 90 days ]
Distribution of the modified Rankin Scale scores at 90 days (shift analysis)
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: February 7, 2021)
  • Proportion of Patients with Functional independence in 90 days [ Time Frame: 90 days ]
    Functional independence defined as mRS ≤2
  • Disability on the utility-weighted modified Rankin scale (UW-mRS) [ Time Frame: 90 days ]
    Mean score for disability on the utility-weighted modified Rankin scale (UW-mRS). The score range from 1 to zero with higher values indicating a better functional outcome at 90 days
  • Quality of life measured by EuroQol Group 5-Dimension Self-Report Questionnaire (EuroQol / EQ5D) [ Time Frame: 90 days and 1 year ]
    Quality of life analysis as measured by EuroQol/EQ5D 5-Dimension Self-Report Questionnaire, on which scores range from -0.176 to 1, with higher values indicating a better quality of life]) at 90 days
  • Mortality at 90 days [ Time Frame: 90 days ]
    Mortality at 90 days
  • Proportion of patients with Intracranial Hemorrhage at 24 hours [ Time Frame: 24 hours ]
    Clinically significant ICH rates at 24 (-2/+12) hours. All intracerebral hemorrhages will be classified by a central core-lab using the Heidelberg criteria. Symptomatic ICH will be defined as per the SITS-MOST definition: deterioration in NIHSS score of ≥4 points within 24 hours from treatment and evidence of intraparenchymal hemorrhage type 2 in the 22 to 36 hours follow-up imaging scans.
  • Procedural related complications [ Time Frame: immediately after procedure ]
    Procedural related complications: arterial perforation, arterial dissection, and embolization in a previously uninvolved vascular territory
Original Secondary Outcome Measures  ICMJE
 (submitted: February 4, 2020)
  • Functional independence [ Time Frame: 90 days ]
    Functional independence defined as mRS ≤2
  • disability on the utility-weighted modified Rankin scale (UW-mRS) [ Time Frame: 90 days ]
    Mean score for disability on the utility-weighted modified Rankin scale (UW-mRS)
  • Quality of life (EQ5D): EuroQol/EQ5D [ Time Frame: 90 days, 1 year ]
    Quality of life analysis as measured by EuroQol/EQ5D
  • Mortality [ Time Frame: 90 days ]
    Mortality at 90 days
  • Intracranial Hemorrhage [ Time Frame: 24 hours ]
    Clinically significant ICH rates at 24 (-2/+12) hours. All intracerebral hemorrhages will be classified by a central core-lab using the Heidelberg criteria. Symptomatic ICH will be defined as per the SITS-MOST definition: deterioration in NIHSS score of ≥4 points within 24 hours from treatment and evidence of intraparenchymal hemorrhage type 2 in the 22 to 36 hours follow-up imaging scans.
  • Procedural related complications [ Time Frame: immediately after procedure ]
    Procedural related complications: arterial perforation, arterial dissection, and embolization in a previously uninvolved vascular territory
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Randomization of Endovascular Treatment in Acute Ischemic Stroke in the Extended Time Window
Official Title  ICMJE Randomization of Endovascular Treatment With Stent-retriever and/or Thromboaspiration vs. Best Medical Therapy in Acute Ischemic Stroke Due to Large VEssel OcclusioN Trial in the Extended Time Window
Brief Summary A phase III, randomized, multi-center, open label clinical trial that will examine whether endovascular treatment is superior to standard medical therapy alone in patients who suffer a large vessel anterior circulation ischemic stroke within 8-24 hours from time last seen well
Detailed Description Prospective, multi-center, randomized, controlled, open-label, blinded-endpoint trial with a sequential design. The randomization employs a 1:1 ratio of mechanical thrombectomy with stent-retriever and/or thromboaspiration versus medical management alone in patients who suffer a large vessel anterior circulation ischemic stroke between 8 and 24 hours from time last seen well. Randomization will be done under a minimization process using age (≤68 vs. >68 years), baseline NIHSS (<17 v. ≥17), ASPECTS (5-7 vs. 8-10), therapeutic window (6-12 or 12-24 hours after TLKW), occlusion site (Intracranial ICA or M1), and clinical site. For the primary endpoint, subjects will be followed for 90 days post-randomization. Sham endovascular procedure has been rejected due to the medical risk of the angiography and practical issues that difficult to maintain blindness of investigators.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:
The randomization employs a 1:1 ratio of mechanical thrombectomy with stent-retriever and/or thromboaspiration versus medical management alone
Masking: Single (Outcomes Assessor)
Masking Description:
Sham endovascular procedure has been rejected due to the medical risk of the angiography and practical issues that difficult to maintain blindness of investigators. For the primary endpoint, subjects will be followed for 90 days post-randomization. Distribution of the modified Rankin Scale scores at 90 days will be evaluated by two separate assessors who are blinded to treatment. Primary Endpoint will consider central core lab readings only (video interview with RFA method) with local reading as a back-up mechanism.
Primary Purpose: Treatment
Condition  ICMJE Stroke, Ischemic
Intervention  ICMJE Device: Thrombectomy
Endovascular treatment of large vessel occlusion (mechanical thrombectomy) with stent-retriever and/or thromboaspiration (neurointerventionalist choice)
Other Name: Endovascular treatment
Study Arms  ICMJE
  • Experimental: thrombectomy
    mechanical thrombectomy with stent-retriever and/or thromboaspiration
    Intervention: Device: Thrombectomy
  • Active Comparator: Clinical treatment
    Best Medical treatment
    Intervention: Device: Thrombectomy
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: February 4, 2020)
376
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE May 1, 2022
Estimated Primary Completion Date February 1, 2022   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Acute ischemic stroke where patient is ineligible for IV thrombolytic treatment or the treatment is contraindicated (e.g., subject presents beyond recommended time from symptom onset), or where patient has received IV thrombolytic therapy without clinical improvement.
  2. No significant pre-stroke functional disability (mRS ≤2)
  3. Baseline NIHSS score obtained prior to randomization must be equal or higher than 8 points (assessed within one hour prior to qualifying imaging)
  4. Age ≥18 years (no upper age limit)
  5. Occlusion (TICI 0-1) of the intracranial ICA (distal ICA or T occlusions) and/or MCA-M1 segment suitable for endovascular treatment, as evidenced by CTA, MRA or angiogram, with or without concomitant cervical carotid occlusion or stenosis.
  6. The presence of Age-Adjusted modified Clinical ASPECTS Mismatch (mCAM) defined as ASPECTS 5-10 and one of the following criteria:

    1. NIHSS ≥ 8 and >50% involvement in 0-1 Cortical (e.g. M1-6) ASPECTS areas (any age);
    2. NIHSS ≥ 8 and >50% involvement in 0-2 Cortical (e.g. M1-6) ASPECTS areas (and age < 80 years old);
    3. NIHSS ≥ 15 and >50% involvement in 0-3 Cortical (e.g. M1-6) ASPECTS areas (and age < 80 years old).
  7. Patient treatable within 6-24 hours of symptom onset. Symptoms onset is defined as point in time the patient was last seen well (at baseline). Treatment start is defined as arterial puncture.
  8. Informed consent obtained from patient or acceptable patient surrogate

Exclusion Criteria:

-Clinical criteria

  1. Known hemorrhagic diathesis, coagulation factor deficiency, or oral anticoagulant therapy with INR > 3.0
  2. Baseline platelet count < 30.000/µL
  3. Baseline blood glucose of < 50mg/dL
  4. Severe, sustained hypertension (SBP > 185 mm Hg or DBP > 110 mm Hg) NOTE: If the blood pressure can be successfully reduced and maintained at the acceptable level using AHA guidelines recommended medication (including iv antihypertensive drips), the patient can be enrolled.
  5. Patients in coma defined as totally unresponsive; responding only with reflexes or being areflexic (Intubated patients for transfer could be randomized only in case an NIHSS is obtained by a neurologist prior transportation).
  6. Seizures at stroke onset which would preclude obtaining a baseline NIHSS
  7. Serious, advanced, or terminal illness with anticipated life expectancy of less than one year.
  8. History of life-threatening allergy (more than rash) to contrast medium
  9. Subjects who has received IV t-PA treatment beyond 4.5 hours from the beginning of the symptoms
  10. Woman of childbearing potential who is known to be pregnant or who has a positive pregnancy test on admission.
  11. Subject participating in a study involving an investigational drug or device that would impact this study.
  12. Cerebral vasculitis
  13. Patients with a pre-existing neurological or psychiatric disease that would confound the neurological or functional evaluations, mRS score at baseline must be ≤2. This excludes patients who are severely demented, require constant assistance in a nursing home type setting or who live at home but are not fully independent in activities of daily living (toileting, dressing, eating, cooking and preparing meals, etc.)
  14. Unlikely to be available for 90-day follow-up (e.g. no fixed home address, visitor from overseas).

    - Neuroimaging criteria

  15. Hypodensity on CT or restricted diffusion on MRI amounting to an ASPECTS score of <5.
  16. Complete involvement of more than 3 cortical ASPECTS areas (e.g. M1, M2, M3, M4, M5, or M6).
  17. Complete absence of leptomeningeal collaterals on CT angiography (e.g. Malignant CTA pattern or score 0).
  18. CT or MR evidence of hemorrhage (the presence of GRE microbleeds is allowed).
  19. Significant mass effect with midline shift.
  20. Evidence of ipsilateral carotid occlusion, high grade stenosis or arterial dissection in the extracranial or petrous segment of the internal carotid artery that cannot be treated or will prevent access to the intracranial clot or excessive tortuosity of cervical vessels precluding device delivery/deployment
  21. Subjects with occlusions in multiple vascular territories (e.g., bilateral anterior circulation, or anterior/posterior circulation)
  22. Evidence of intracranial tumor (except small meningioma).
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Sheila CO Martins, MD, PhD 51999628467 scmartins@hcpa.edu.br
Contact: Natacha Fleck 51992699829 pesquisaneurovascular@gmail.com
Listed Location Countries  ICMJE Brazil
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04256096
Other Study ID Numbers  ICMJE 17877519.6.1001.5327
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: Yes
Plan Description: Because of the sensitive nature of the data collected for this study, requests to access the dataset from qualified researchers trained in human subject confidentiality protocols may be sent to the principal investigators
Supporting Materials: Study Protocol
Supporting Materials: Statistical Analysis Plan (SAP)
Supporting Materials: Informed Consent Form (ICF)
Supporting Materials: Clinical Study Report (CSR)
Time Frame: after de publication for 6 months
Access Criteria: Because of the sensitive nature of the data collected for this study, requests to access the dataset from qualified researchers trained in human subject confidentiality protocols may be sent to the principal investigators
Responsible Party SHEILA CRISTINA OURIQUES MARTINS, Hospital de Clinicas de Porto Alegre
Study Sponsor  ICMJE Hospital de Clinicas de Porto Alegre
Collaborators  ICMJE
  • Hospital das Clínicas de Ribeirão Preto
  • Hospital Geral de Fortaleza
  • Hospital de Base
  • Federal University of São Paulo
  • Fundação Faculdade Regional de Medicina de São José do Rio Preto
  • UPECLIN HC FM Botucatu Unesp
  • University of Campinas, Brazil
  • Irmandade Santa Casa de Misericórdia de Porto Alegre
  • Universidade Federal do Paraná
  • Hospital Estadual Central
  • Hospital Sao Jose do Avai
  • Irmandade da Santa Casa de Misericordia de Sao Paulo
  • Federal University of Uberlandia
  • Instituto de Assistencia Medica ao Servidor Publico Estadual, Sao Paulo
Investigators  ICMJE
Principal Investigator: Raul G Nogueira, MD Emory University
Principal Investigator: Sheila CO Martins, MD, PhD Hospital de Clinicas de Porto Alegre
PRS Account Hospital de Clinicas de Porto Alegre
Verification Date February 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP